摘要
抑郁症是一种以显著而持久的心境低落为主要临床特征的常见的情感性精神疾病,已成为现代社会的常见病、多发病。研究表明,抑郁症状的发生、发展与神经内分泌系统、免疫系统和基因表达调节的异常有关。抑郁症的治疗主要是药物治疗,目前临床上主要用药有以氟西汀为代表的5-羟色胺(5-HT)再摄取抑制剂(SSRIs),以阿米替林为代表的三环类抗抑郁药(TCA)和以吗氯贝胺为代表的单胺氧化酶抑制剂(MAOI),这些化工合成的药物均有一定疗效,但也均有不同程度的副作用和依赖性,有的甚至反而加重病人抑郁状态。因此,开发疗效确切、毒副作用小的中药,正成为当前国内外抗抑郁药物研发的热点。
本文由中药新药SXY-006的抗抑郁作用评价及其抗抑郁机制研究两部分组成,旨在通过一系列经典行为学和形态学实验,对中药新药SXY-006进行抗抑郁作用研究,并探讨其抗抑郁作用的机制,为其投入临床应用提供理论和实验依据。
第一部分中药SXY-006的抗抑郁作用
目的:研究中药SXY-006的抗抑郁作用
方法:通过小鼠悬尾实验、小鼠强迫游泳实验、大鼠单次及多次给药后强迫游泳实验,观察中药SXY-006对实验动物不动时间的影响;通过制作大鼠慢性轻度不可预见性应激(CUMS)抑郁症模型,进行敞箱(open-field)实验,观察SXY-006对实验动物水平得分和垂直得分的影响。
结果:SXY-006中剂量(100 mg/kg)、高剂量(300 mg/kg)均能明显减少小鼠悬尾实验和强迫游泳实验的不动时间(p<0.01); SXY-006低(25 mg/kg)、中(100 mg/kg)、高(300 mg/kg)剂量均能减少大鼠单次和多次给药后强迫游泳实验的不动时间(p<0.05),均能增加大鼠慢性不可预知性应激抑郁症造模后大鼠的水平得分(p<0.05)和垂直得分(p<0.01)。
结论:中药新药SXY-006具有抗抑郁作用
第二部分中药SXY-006抗抑郁作用的机制
目的:研究中药SXY-006抗抑郁作用的机制
方法:通过5-羟色胺酸(5-HTP)诱导的小鼠甩头实验观察SXY-006对小鼠甩头次数的影响;通过利血平引起的小鼠睁眼不能以及运动不能实验观察SXY-006对小鼠眼睑闭合和自主运动的影响;通过HE染色观察海马神经元形态学的变化,免疫组织化学技术检测5-HT2受体、c-fos蛋白的表达。
结果:SXY-006低剂量(25 mg/kg)、中剂量(100 mg/kg)和高剂量(300 mg/kg)均能显著增加5-HTP诱导的甩头实验中小鼠甩头次数(p<0.01),均能拮抗利血平引起的小鼠的睁眼不能和运动不能(p<0.05);抑郁症模型组大鼠海马神经元形态异常,顶叶皮层5-HT2受体、海马c-fos蛋白表达增加,而SXY-006各剂量组大鼠海马神经元形态基本正常,5-HT2受体、c-fos蛋白表达无明显变化。
结论:中药SXY-006的抗抑郁作用可能与其①阻断突触间隙单胺类递质再摄取或抑制单胺氧化酶,②对海马神经元的保护作用,③下调5-HT2受体和c-fos受体的作用有关。
Depression is a common and debilitating thymogenic mental disorder in clinic, characterized by marked and long-lasting depressed mood. Previous studies show that the pathogenesis of depression correlates with the abnormity of neuroendocrine and immune system and the expression of certain genes. Depression is primarily treated by drug therapy. The clinically used medications include selective serotonin reuptake inhibitors(SSRIs, e.g. fluoxetine)、TCAs (e.g. amitripramine) and monoamine oxidase inhibitor (MAOIs, e.g. maclobemide). All of the drugs are effective in treating some subpopulation of depression patients, however, they also have certain side effects or physical dependence, and under some conditions they even aggravate the process. Therefore, it is necessary to find new drug, which has good antidepressive effect and less adverse reaction.
The thesis consists of two parts: preclinical evaluation of the antidepressant efficacy of new TCM SXY-006 and the investigation of its mechanism. By using several behavioral and morphological experiment for antidepressants, the goal of this series of studies is to evaluate the antidepressant effects of SXY-006 and elucidate its mechanisms, thus to provide convinced preclinical information for NDA (New Drug Application).
Part I Antidepressant effects of traditional Chinese medicine“SXY-006”
Objective: To evaluate the antidepressant effects of traditional Chinese medicine“SXY-006”
Methods: The effect of SXY-006 on immobility time was investigated by the tail suspension test and force swimming test of mice or rats after single and multiple administrations. The effect of SXY-006 on horizontal and vertical score was studied through the open-field test after the establishment of chronic unpredictable mild stress (CUMS) model of rats.
Results: Moderate (100 mg/kg) and high (300 mg/kg) doses of SXY-006 can obviously decrease the immobility time in the tail suspension and forced swimming tests of mice (p<0.01). All of SXY-006 in different doses can markedly reduce the immobility time in forced swimming tests of rats after both the single and multiple administrations of the medicine (p<0.05), and raise the horizontal score (p<0.05) and vertical score (p<0.01) in chronic unpredictable mildstress model of rats.
Conclusion: The new TCM SXY-006“SXY-006”has good antidepressant effect.
PartⅡAntidepressant mechanisms of traditional Chinese medicine“SXY-006”
Objective: To investigate antidepressant mechanisms of traditional Chinese medicine“SXY-006”
Methods: The effect of SXY-006 on the times of 5-HTP induced head-twitches and reserpine induced eyes shutting and independence movement were observed. HE stain was applied to observe the morphological change of hippocampal neurons. The expression of the 5-HT2 and c-fos were analyzed by immunohistochemistry experiment.
Results: Different doses of SXY-006 can markedly increase the times of head-twitches induced by 5-HTP of mice (p<0.01). It can antagonize the inability of eyes opening and akinesia evoked by reserpine (p<0.05). In the depression model group, the morphology of neurons in the hippocampus is aberrant, and the expression of 5-HT2 and c-fos increase significantly in parietal cortex and hippocampus. However, SXY-006 improve the morphology of neurons in the hippocampus, and different SXY-006 groups had no changes in the expression of 5-HT2 and c-fos.
Conclusion: The traditional Chinese medicine“SXY-006”exerts antidepressant effect probably through①inhibiting the reuptake of monoamine in synaptic cleft or inhibiting monoaminoxidase,②protecting hippocampal neurons,③decreasing the expression of 5-HT_2 and c-fos.
引文
1. Katz RJ, Roth KA, Carroll BJ. Acute and chronic stress effects on open field activity in the rat : implications for a model of depression[J]. Neuroscience Biobehavioral Reviews,1981,5:247.
2. Steru L,Chermat R,Thicrry B,et al. The tail suspension test: A new method for screening antidepressants in mice [J].Psychopharmacology,1985,85:367-370.
3. Porsolt R,Le pichon M. Depression:a new method animal model sensitive to antidepressant treatments[J]. Nature,1977,266:730-732.
4. Porsolt RD. Bertin A. Jalfre M. Behavioral despair in mice: A primary screening test for antidepressant [J]. Arch Int Pharmacol Ther,1977,229:327-336.
5. Willner P. Validity , reliability and utility of the chronic mild stress model of depression : a 10 - year review and evaluation [J ] . Psychopharmacology ( Berl ) , 1997 , 134 : 319~329.
6. Borsini F ,Voltera G,Meli A. Does the Behavioral Despair Test Measure?Physiology &Behavior ,2003 ,(38) :385.
7. Betin C,De Feudis FV, Blavet N, et al.Further characterization of the behavioural despair in mice: Positive effects of convulsants[J].Physio-Behav,1982,28:307-311.
8. Kitada Y, Miyauchi T,Satoh A,et al.Effects of antidepressants in the rat forced swimming test[J].Eur J pharmacol,1981,72:145-152.
1 Takeuchi H, Yatsugi S, Hatanaka K,et al.Pharmacological studies on YM992, a novel antisepressant with selective serotonin re-uptake inhibitory and 5-HT2A receptor antagonistic activity.Eur L Pharmacol 1997; 329(1): 27-35.
2 Sparenberg B, Demisch L, Holzl J. Untersuchungen uber antidepressive Wirkstoffe von Johanniskraut Pharm Ztg Wiss, 1993, 22: 194.
3张均田.现代药理实验方法[M].第1版.北京;北京医科大学中国协和医科大学联合出版社, 1998, 1049.
4 Blows WT. The neurobiology of antidepressants. J NeurosciNurs, 2000, 32(3): 177-180.
5 Charney DS, Heninder GR, Sternberg DE, et al. Adenergic receptor sensitivity in depression: effects of clonidine in depression patients and health subjects. Arch Gen Psychiat, 1982, 39: 290-294.
6 Meltzer HY, Lowy MT. Serotonin hypothesis of depression. Psychopharmacology: The third generation of progress, 1987, 92: 513-526.
7 Du L, Bakish D, Lapierre YD, et al. Association of polymorphism of serotonin 2A receptor gene with sucidal ideation in major depressive disorder. AmJ Med Genet, 2000, 96: 56.
8 Franza J R, Frank J, Rauscher, et al. The Fos Complex and Fos-Related Antigens Recognize Sequence Elements That Contain AP21 Bending sites. Science, 1988, 239: 1150.
9孙欣,刘昌勤,习得性无助大鼠脚底电刺激后海马c-fos表达,中国康复2005年8月第20卷第4期, 201-203.
10 Senba E, Ueyama T. Stress-induced expression of immediate early genesin the brain and peripheral organs of the rat. Neuroscience Research, 1997, 29: 183-207.
11 Sagar SM, Sharp FR, Curran T. Expression of fos protein in brain: metabolic mapping at the cellular level. Science, 1988, 240: 1328-1331.
12 Cullinan WE, Herman JP, Battaglia DF, et al. Pattern and time course of immediate earlygene expression in rat following acute st ress[J]. Neuroscience, 1995, 65(2) :477 - 477.
[1]沈渔村.精神病学[ M] .第3版.北京:人民卫生出版社,1994 : 631
[2]全国情感障碍亚型家系研究协作组.单相抑郁与双相情感障碍遗传效应及方式的对照研究[J ] .中华精神科杂志, 1997 , 30(4) : 199– 202
[3] Holmes C , Russ C , Kirov C , et al. Apolipoprotein E: Depressive illness , depressive symptoms and alzheimer disease [ J ] . Biol Psy2 chiatry , 1998 , 43 (2) : 159– 164
[4] Owens MJ , Nemeroff CB. The role of serotonin in the pathophysiology of depression : focus on the serotonin transporter[J] . Clin Chem ,1994 ,(40) :288-295.
[5] Feldstein A , Hoagland H , Rivera Oktem M, et al . MAO inhibition and antidepressant activity [ J ] . Int J Neuropsychiatry ,1965 ,1(4) :384~387.
[6] Goodwin FK, Bunney WE. Depressions following reserpine : A reevaluation[J ] . Semin Psychiatry , 1971 ,3(4) :435~448.
[7] Schildkraut JJ . The catecholamine hypothesis of affective disorders : A review of supporting evidence [J ] . Am J Psychiatry ,1965 ,122(5) :509~522.
[8] Bunney WE , Davis JM. Norepinephrine in depressive reactions : A review[J ] . Arch Gen Psychiatry , 1965 ,13(6) :483~494.
[9] Racagni G, Brunello N. Physiology to functionality : The brain and neurotransmitter activity [J ] . Int Clin Psychopharmacol ,1999 ,14 (Suppl 1) : 3~7.
[10] Nemeroff CB. The neurobiology of depression [ J ] . Sci Am , 1998 ,278(6) : 42~499.
[11]张有志,柴地合方对慢性应激大鼠大脑前额皮质和海马单胺类神经递质的影响.安徽中医学院学报,第24卷第1期2005年2月34-36.
[12]韩济生.神经科学原理[M] .北京:北京医科大学出版社,199911132-1144.
[13] Dinan TG. Noradenergic and serotonergic abnormalities in depression: strss-induced dysfunction [ J ] . J Clin Psychiatry , 1996 , 57(Suppl 4) :14-18.
[14] Gerra G, Zaimovic A , Zambelli U , et al . Neuroendocrine correlates of depression in abstinent heroin2dependent subjects[J ] . Psychiatry Res , 2000 ,96 (3) :221-234.
[15] Blier P.抑郁症治疗的进展和趋势.徐积恩,译.国外医学药学分册,1995 ,22 :27230.
[16]李焕德,朱运贵,易清华.抗抑郁药及其临床应用的研究进展(综述) .国外医学药学分册, 1998 , 25 :2282232.
[17] Basedovsky HO, et al1 Network of immune neuroendocrine interactions1 Clin Exp Immunol, 1977, 27∶1
[18] Mizoguchi K, et al1 Chronic stress differentially regulates glucocorticoid negative feedback response in rats1 Psychoneuroendocrinology, 2001, 26∶443
[19] Connor TJ , et al1 Forced swim-test-induced endocrine and immune change in the rat: effect of subacute desip ramine treatment1 J PharmacolBiochem Behav, 1998, 59 (1)∶171
[20] ReusV I, et al. Antiglucocoiticoid treatment in p sychiatry.J Psychoneuroendocrinology, 1997, 22 ( suppl .1)∶121
[21] WU DH, YANG Q. The mechanism of hippocampus injury induced by chronic stress [J]. J Shantou Univ Med Coll Bull(in Chinese),2001,14(4):270-271.
[22]喻东山.抑郁症的生化和解剖基础.四川精神卫生,2001,14(1):60~62
[23] Sheline YI , Sanghavi M, Mintun MA , et al . Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression[J ] . J Neurosci ,1999 ,19 : 5034 - 5043.
[24] Wissink S ,Meijer O ,Pearce D ,et al . Regulation of the rat serotonin-1A receptor gene by corticosteroids [ J ] . J Biol Cham ,2000 ,275(2) :1321- 1326.
[25]高晓玲,王哲蔚,华嘉增,等.更年期妇女抑郁症状的发生情况及影响因素的研究[J ] .中国妇幼保健, 1998 , 13 (5) : 294– 296
[26]赵更力,鲍月琴,渠川琰,等.更年期妇女抑郁症状的发生情况及影响因素[J ] .中华妇产科杂志, 1996 , 31 (10) : 614– 616
[27]陈昌惠.应激与健康[J ].中国心理卫生杂志, 1987 , 1 (5) : 225 -229
[28] Levy EM. Biological measures and celluar immunological function in depressed psychiatric inpatients[J ] . Psychiatry Research , 1991 , 36 (2) : 157– 167
[29] Janice K, Kiecolt2Glaer , Laura D , et al. Marital quality , marital disruption and immune funtion [ J ] . Psychosom Med , 1987 , 49(1) ; 13– 14
[30]骆晓林,陈昌惠,李淑然,等. 45岁以上抑郁病人与正常人心理、免疫功能的比较研究[J ] .中国临床心理杂志, 1997 , 5 (2) :83– 86
[31]余西金.应激事件和重性抑郁发作的因果关系[J ] .国外医学·精神病学分册, 2000 , 27 (1) : 51– 52
[32] Willner P1 A animal models as simulations of depression1 TIPS , 1991 ,12 :131-137.
[33] Redei EE , Ahmadiyeh N , Baum AE , et al1 Novel animal models of affective disorders1 Semin Clin Neuropsychiatry , 2001 , 6 : 43-67.
[34] Papp M, Klimek V , willner P1 Effects of imipramine on serotonergic and beta2adrenergic receptor binding in a realistic animal model of depression1 Psychopharmacology , 1994 , 114 :309-314.
[35] Blows WT. The neurobiology of antidepressants. J NeurosciNurs ,2000 ,32(3) : 177~180
[36]刘艳梅,祁红,陈红专.氟西汀对荷瘤小鼠抑郁状态的改善作用[A].见:中国新药与临床杂志, 2005年10月,第24卷第10期, 757-759
[37]晏忠,罗质璞.抗抑郁药理实验方法[A] .见:张均田主编.现代药理实验方法[M] .北京:北京医科大学中国协和医科大学联合出版社,1998. 1061 - 1071.
[38] Kato M, Katayama T, Iwata H , et al. In vivo characterization of T- 794 , a novel reversible inhibitor of monoamine oxidase-A , as an antidepressant with a wide safety margin[J ] . J Pharmacol Exp Ther , 1998 , 284(3) :983 - 990.
[39] Joop S. de G, Henk VR , Hemmie HG, et al. A set of be havioural tests predicting and antidepressant activity[J ] . Drug Develop Res , 1985 , 5(2) :291 - 301.
[40] Borsin F , Brambilla A , Grippa N , et al. Behavioral effects of flibanserin(BIMT 17) [J ] . Pharmacol Biochem Behav , 1999 ,64 (1) :137 - 146.
[41] Joop S. de G, Henk VR , Hemmie HG, et al. A set of be havioural tests predicting and antidepressant activity[J ] . Drug Develop Res , 1985 , 5(2) :291 - 301.
[42]李明亚,李娟好,季宁东,郭丽冰,甘火荣,庄岚[A].广东药学院学报,第20卷第2期2004年4月,141-144
[43] Seligman ME , Beagly G. Learned helplessness in the rat[J ] . J Comp Physiol Psychol , 1975 , 88(2) :534 - 541.
[44] Eisenstein EW, Carlson AD , Harris JT1 A ganglionic model of“learned helplessness”Integr Physiol Behav Sci , 1997 , 32 :265-271
[45] Willner P. Validation criteria for animal models of human mental disorders: learned helplessness as paradigm case. Prog Neuropsychopharmacol Biol Psychiatry, 1986, 10(6): 677-690
[46] Porsolt RD , LePichon M, Jalfre M, et al. Depression : A new animal model sensitive to antidepressant treatment [J ] . Nature , 1977 , 266(5604) :730 - 732.
[47] Willner P , Towell A , Sampson D , et al1 Reduction of sucrose preference by chronic mild unpredictable stress and its restoration by a tricyclic antidepressant1 Psychopharmacology , 1987 , 93 :358-364
[48] Reid L , Forbes NF , Stewart C , et al1 Chronic mild stress and depressive disorder : a useful new model ? Psychopharmacology , 1997 , 134 : 365-367
[49] Vry LD , Schreiber R1 The chronic mild stress depression model : future dvelopments from a drug discovery perspective1 Psychopharmacology , 1997 , 134 :349-350
[50] Willner P1 Validity , reliability and utility of the chronic mild stress model of depression : a 102year review and evaluation1 Psychopharmacology , 1997 , 134 :319-329
[51] Porsolt RD1 Animal models of depression : Utility for transgenic research1 Rev Neurosci , 2000 , 11 :53-58
[52] Richardson JS. Animal model of depression reflect changing views on the essence and etiology of depressive disorders in humans [ J ] . Prog Neuropsychopharmacol Biol Psychiatry , 1991 , 15(2) :199 - 204.
[53] Suomi SJ , Delizio R , Harlow HF. Social rehabilitation of separation - induceddepressive disorders in monkeys [J ] .Am J Psychiatry , 1976 , 133(11) :1279 - 1285.
[54] Hennessy MB , Deak T , Schiml Webb PA Stress induced sickness behaviors: an alternative hypothesis for responses during maternal separation Dev Psychobiol , 2001 , 39 : 76-83
[55] Slotkin TA , Seidler FJ , Ritchie JC1 Regional differences in brain monoamine oxidase subtypes in an animal model of geriatric depression: effects of olfactory bulbectomy in young versus aged rats1 Brain Res , 2000 , 882 : 149-154
[56] Stock HS , Ford K, Wilson MA1 Gender and gonadal hormone effects in the olfactory bulbectomy animal model of depression1 Pharmacol Biochem Behav , 2000 , 67 : 183-191.
[57] Galea LA , Wide JK, Barr AM1 Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression, Behav Brain Res , 2001 , 122 : 129.
[58]王永龙.临床医药实践,2003 ,12 (1) :20– 20
[59]张宏根,丁杰豪,赵靖平,陈远光.中国新药杂志,1998 ,7 (5) :366– 368
[60]王树阳,牛俊红,等.河北精神卫生,2002 ,15 (1) :31– 32
[61]付鹃.中国民政医学杂志,2002 ,14 (6) :339– 340
[62]杨东英,陆小兵等.四川精神卫生,2002 ,15 (3) :142– 143
[63]崔炳喜,田红军.天津药学,2002 ,14 (2) :49– 50
[64]邹来英,陈光金,等.山东精神医学,2002 ,15 (2) :89– 90
[65]孟焱,杜江,等.新乡医学院学报,2002 ,19 (3) :181– 183
[66]秦国兴,田国强.健康心理学杂志,2002 ,10 (1) :35– 36
[67]王爱荣,张仲荣.医药导报,2002 ,21 (3) :163– 164
[68] Makhija , SN Vavia , Once daily sustained release tablets of venlafaxine ,a novel antidepressant [J ]. Eur - J - Pharm -Biopharm ,2002 J ul ,54 (1) :9– 15
[69]解克平,韩莹,等.健康心理学杂志,2002 ,10 (4) :252– 253
[70]陈晓岗,赵靖平,等.中国临床康复,2002 ,6 (15) :2300– 2307
[71]陆峥,刘帼芳,林治光,等.临床精神医学杂志,2002 ,12 (5) :259– 260
[72]李刚,梁海翔.四川精神卫生,2002 ,15 (2) :92– 93
[73]白克镇,龚科,等.泸州医学院学报,2002 ,25 (6) :522– 523
[74]张明.中国临床康复,2002 ,6 (15) :2302– 2302
[75]李一云,刘玉局等.四川精神卫生,2002 ,15 (1) :22– 23
[76]闫孔亚,王世纪等.中医杂志,2002 ,43 (11) :835– 836
[77]谭友果.国外医学:精神病学分册,2002 ,29 (4) :201– 204
[78]管宇宙,崔丽英,汽晓芙等.中华神经科杂志,1999 ,32 (5) :311– 313
[79]吴志亮.国际医药卫生导报,2002 , (02B) :120 - 121
[1]童南伟,梁荩忠。一种新的长效碘脲类降糖药:格列美脲[J]。中国糖尿病杂志,2000,8(4):238~239.
[2] Lehr-KH, Damm-P. Simultaneous determination of the sulphonylurea glimepiride and its metabolites in human serum and urine by high-performance liquid chromatography after pre-colomn derivatization[J]. J Chromatogr , 1990 ,526(2):497~505.
[3] Langtry HD,Balfour JA. Glimepiride: a review of its use in the management of type 2 diabetes mellitus[J]. Drugs,1998,55(4):563~584.
[4] Rosenkranz B. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients[J]. Horm Res Metab,1996,28(9):434~439.